BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration – StreetInsider.com
|
BioLineRx (BLRX) Begins Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration
StreetInsider.com The clinical study collaboration between BioLineRx and Genentech, a member of the Roche Group, is part of MORPHEUS, Roche’s Novel Cancer Immunotherapy Development Platform. MORPHEUS is a phase 1b/2 adaptive platform to assess the efficacy … |
|
上海生科院建立高效谷氨酸棒杆菌CRISPR-Cpf1基因组编辑系统
新浪网 5月4日，《自然-通讯》（Nature Communications）发表了中国科学院上海生命科学研究院植物生理生态研究所合成生物学重点实验室杨晟研究组题为CRISPR-Cpf1 assisted genome editing of Corynebacterium glutamicum 的 … |
|
上海生科院建立高效谷氨酸棒杆菌CRISPR-Cpf1基因组编辑系统
新浪网 5月4日，《自然-通讯》（Nature Communications）发表了中国科学院上海生命科学研究院植物生理生态研究所合成生物学重点实验室杨晟研究组题为CRISPR-Cpf1 assisted genome editing of Corynebacterium glutamicum 的 … |
|
Study That Claims CRISPR Causes Unwanted Mutations Is Probably Wrong
ScienceAlert If that was the case, we would have to seriously reconsider the safety of CRISPR, especially when used on humans. But now a paper has been published online claiming it was all a mistake, and the authors of the original study were doing a “disservice to … |